-
Major breakthrough in first-line treatment of liver cancer! Is this immune combination therapy expected to change the treatment mode?
Time of Update: 2019-10-22
Roche announced that tecentriq (atezolizumab, atzumab), a blockbuster PD-L1 inhibitor, combined with Avastin (bevacizumab), an anti VEGF antibody, reached two common primary endpoints in phase 3 clini
-
New immunotherapy! Nektar's immunostimulatory therapy, IL-15 signal pathway activator nktr-255, has entered human clinical practice!
Time of Update: 2019-10-22
October 22, 2019 / BIOON / - nektar Therapeutics recently announced the launch of the first human phase I clinical study to evaluate nktr-255, an interleukin-15 (IL-15) receptor agonist, which will ev
-
Nat commun: immunosuppressant resistance is related to metabolic imbalance
Time of Update: 2019-10-21
October 21, 2019 / bioun / -- Dana Farber Cancer Institute, in collaboration with the broad Institute of MIT and Harvard University, reported that metabolic imbalance in some cancer patients after tre
-
Cell Rep: revealing the cause of rapid growth of malignant pancreatic cancer
Time of Update: 2019-10-20
October 20, 2019 / Biogen / - a new discovery on pancreatic cancer reveals how pancreatic cancer promotes its growth and may help explain how promising anticancer drugs work and which cancers they are
-
It is expected to treat squamous cell carcinoma of the head and neck. The anti-PD-1 antibody of mosadon has won the positive evaluation of the European Drug Commission
Time of Update: 2019-10-19
MSD today announced that the European Drug Administration's Committee on human medicinal products (CHMP) recommended approval of two options of keytruda (anti PD-1 therapy of MSD) for the first-line t
-
FASEB J: find a new target for the treatment of pancreatic cancer! The king of cancer shivers!
Time of Update: 2019-10-18
October 18, 2019 / BIOON / -- a recent study in the journal FASEB found a new mechanism of pancreatic cancer resistance to chemotherapy Its mechanism includes the loss of PML function, which is simila
-
BJC: discover new ways to use the immune system to treat cancer
Time of Update: 2019-10-18
October 18, 2019 / BIOON / -- a study published in the British Journal of cancer recently found that a naturally occurring molecule and an integral part of the immune system can successfully target an
-
NEJM news: combined immunotherapy significantly improves the long-term survival rate of melanoma patients
Time of Update: 2019-10-17
October 17, 2019 / bioun / - according to a study by the NHS Foundation in Royal Marsden, a combination of two immunotherapeutic drugs, ipilimumab and nivolumab, has prevented or reversed the progress
-
Tumor immunotherapy! Lilly's $1.6 billion acquisition of the IL-10 project pegilodecakin first-line treatment of pancreatic cancer phase III clinical failure!
Time of Update: 2019-10-17
October 17, 2019 / Biovalley BIOON / - Eli Lilly, an American pharmaceutical giant, recently published the top line results of the phase III seqoia study, which was carried out in patients with metast
-
Science subjournal: Central South University develops natural halloysite nanotubes to deliver small interfering RNA for bladder cancer treatment
Time of Update: 2019-10-17
October 17, 2019 / Bio Valley bio on / -- RNA interference (RNAi) technology can specifically silence the expression of target genes, which is a promising cancer treatment method Recently, researchers
-
J Hepatol: the researchers showed the potential of targeting cancer stem cells to treat liver cancer
Time of Update: 2019-10-17
October 17, 2019 / BIOON / -- liver cancer is the second largest cancer-related death cause in the world The most common primary liver cancer in adults is called liver cell carcinoma (HCC) About 78000
-
Research shows that skin cancer above the neck is more likely to metastasize!
Time of Update: 2019-10-16
October 16, 2019 / Bio Valley bio on / - a new 6-month descriptive clinical study shows that cervical malignant melanoma (mm) is more likely to spread than subcervical malignant melanoma However, alth
-
I-mab biopharma announces the approval of new immunotherapy for clinical trials of multiple myeloma in China
Time of Update: 2019-10-15
I-mab biopharma, a clinical biopharma company headquartered in China and the United States, is dedicated to the discovery and development of new or highly differentiated biological agents in immunoonc
-
Vitamin D and fish oil are expected to prevent cancer, death and heart attack
Time of Update: 2019-10-13
October 13, 2019 / BIOON / -- vitamin D and omega-3 test (vital) is the largest and latest test to test whether vitamin D or fish oil can effectively prevent cancer or cardiovascular disease Although
-
Cell: anti cancer with fat cells? Gu Zhen's team develops a new anti-cancer strategy for adipocytes
Time of Update: 2019-10-13
October 13, 2019 / bioun / -- researchers from Jonsson comprehensive cancer center at UCLA have found a new drug delivery pathway that may help prevent tumor growth and cancer recurrence in mice In pr
-
Immunotherapy improves one-year survival rate of esophageal cancer patients in China
Time of Update: 2019-10-12
From September 27 to October 1, one of the most famous and influential professional oncology academic conferences in the world, "2019 European Society of oncology and Internal Medicine annual meeting
-
Immunotherapy for bladder cancer! The first-line treatment of Roche tecentriq + platinum containing chemotherapy was successful in phase III, which significantly prolonged the progression free survival period!
Time of Update: 2019-10-08
October 8, 2019 / BIOON / -- Roche, a Swiss pharmaceutical giant, recently announced the positive results of imvigor130, a phase III clinical study of PD-L1 tumor immunotherapy tecentriq (atezolizumab
-
Good news! Keysruda is the third indication approved by China for the treatment of PD-L1 positive lung cancer!
Time of Update: 2019-10-08
October 8, 2019 / BIOON / -- cancer immunotherapy giant Merck& CO) recently announced that China National Drug Administration (nmpa) has approved keytruda (pembrolizumab, general name: pembrolizumab)
-
Triple negative breast cancer (TNBC) breakthrough! Keytruda combined with neoadjuvant / adjuvant chemotherapy significantly improved the pathological remission of early TNBC!
Time of Update: 2019-10-08
October 8, 2019 / bioun / -- cancer immunotherapy giant Merck & Co recently announced the positive results of keytruda (pembrolizumab, pabolizumab) as a key new adjuvant / adjuvant phase III clinical
-
Immunotherapy for esophageal squamous cell carcinoma (ESCC)! Compared with chemotherapy, the second-line treatment of bosimer opdivo significantly prolonged the total survival time!
Time of Update: 2019-10-08
October 8, 2019 / BIOON / -- Bristol Myers Squibb (BMS) recently announced the results of the phase III clinical study on the treatment of esophageal squamous cell carcinoma (ESCC) by PD-1 tumor immun
